GHRP-6
The pioneer hexapeptide that launched the GHRP class and indirectly led to the discovery of ghrelin.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
GHRP-6
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
2 articles sourced
Knowledge Graph
(3 connections)Research Evidence
(2)Growth Hormone Secretagogues and IGF-1 Axis Research
Examination of GHRH, GHRP, and ghrelin mimetic mechanisms in GH secretion and IGF-1 axis research.
Peptide Synergy: Growth Hormone Secretagogue Stacking
Evidence-based review of GH secretagogue peptide synergy, examining pulsatile GH release, receptor mechanisms, and combination protocols.
Overview
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that was the first commercially viable GHRP compound. Developed in the 1980s, GHRP-6 played a foundational role in growth hormone secretagogue research, leading to the eventual discovery of the ghrelin receptor and the endogenous ligand ghrelin. GHRP-6 remains an important reference compound in GHS research.
Mechanism of Action
GHRP-6 acts as an agonist at the ghrelin receptor (GHS-R1a), stimulating the release of growth hormone from the anterior pituitary. Unlike GHRH, which acts through a separate receptor, GHRP-6 acts through the ghrelin receptor, producing synergistic effects when combined with GHRH or GHRH analogs. GHRP-6 also stimulates the release of ACTH and cortisol, and produces a strong hunger-stimulating (orexigenic) effect through ghrelin receptor activation in the hypothalamus. The hunger effect distinguishes GHRP-6 from more selective GHRPs like Ipamorelin.
Research Highlights
Clinical studies established GHRP-6's efficacy in stimulating GH release in a dose-dependent manner. Research demonstrated the synergistic effects of GHRP-6 combined with GHRH, producing GH elevations greater than either compound alone. Studies explored its potential in growth hormone deficiency, catabolic states, and as a research tool for studying the GH axis. The discovery that GHRP-6 acts through a receptor distinct from GHRH led to the identification of the ghrelin receptor and the subsequent discovery of ghrelin as the endogenous ligand — a landmark in endocrine research.
Dosage & Administration
In research, GHRP-6 has been administered via subcutaneous injection at doses of 100-150 mcg per administration, typically 2-3 times daily. For research use only (RUO).
Safety Profile
Common side effects include increased appetite (hunger), water retention, and transient cortisol elevation. The cortisol and ACTH stimulation distinguishes GHRP-6 from more selective GHRPs. Mild injection site reactions may occur. Long-term safety data is limited. Not approved by the FDA for any indication.
References
Bowers CY, et al. GHRP-6 and GH release. J Clin Endocrinol Metab. 1990. Howard AD, et al. GHS-R receptor discovery. Science. 1996. Kojima M, et al. Ghrelin discovery. Nature. 1999. All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.